Data collection and unification of the results in various papers suggest IRF4, NUCB1, and to a lesser extent, ANXA5 proteins as potential biomarkers that need further investigation in regard to DLBCL prognosis, chemoresistance, and sub-classification. This evidence concerns the gene IRF4 and diffuse large B-cell lymphoma.